DEI BioPharma Ltd3月 2026のための市場シェア分析

Opposition Leader Joel Ssenyonyi Visits Dei BioPharma Facility in Matugga MATUGGA, September 19, 2024 – The sun shone brightly over the Dei BioPharma drugs and vaccines manufacturing facility, casting a warm glow over the sprawling complex in Matugga, Wakiso District. As anticipation filled the air, a convoy of sleek cars arrived, bringing a distinguished delegation of Opposition Members of Parliament (MPs), led by Leader of the Opposition Joel Ssenyonyi. Upon arrival, the delegation stepped onto the polished concrete floors of the 150-acre facility, greeted by the hum of advanced machinery and the chatter of employees. The visitors exchanged warm smiles and handshakes, their expressions reflecting a mix of pride and curiosity. Mr. Ssenyonyi and members of the Shadow Cabinet were given a guided tour by Dr. Matthias Magoola, Founder and Managing Director of Dei BioPharma, assisted by key members of the management team, including Board Chairperson Dr. Patrick Wakida, Chief Pharmacist Dr. Arthur Kayanja, and other senior officials. As they moved through the facility, employees watched with interest and enthusiasm, eager to showcase their work and share their experiences. Mr. Ssenyonyi commended the progress made so far and appreciated the facility’s openness to scrutiny. “We will keep coming and following up to ensure there’s value for the money invested,” he emphasized. He further urged Dei BioPharma to speed up vaccine production to reduce reliance on imported vaccines. Dr. Magoola’s Commitment to Innovation In response, Dr. Magoola expressed gratitude to the MPs for their support and assured them of the company’s commitment to delivering quality pharmaceutical products. He explained that the manufacturing plant project consists of 10 specialized facilities, each dedicated to: The facility also houses the YKTM GLP Biotech Laboratories, which conduct research in: Dr. Magoola highlighted that five of the ten components—including the generics section, warehousing facili